<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04902365</url>
  </required_header>
  <id_info>
    <org_study_id>NeurofeebackSnow</org_study_id>
    <nct_id>NCT04902365</nct_id>
  </id_info>
  <brief_title>Neurofeedback in Visual Snow</brief_title>
  <official_title>Neurofeedback for Patients With Visual Snow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>USZ Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Visual snow (VS) is a distressing, life-impacting condition with unrelenting and persistent&#xD;
      disturbing visual phenomena. Disease onset is usually around age 20 and is characterized by&#xD;
      continuous perception of innumerable flickering dots (like a 'broken television'). The&#xD;
      disease is often accompanied by comorbidities such as migraine, tinnitus, depression and&#xD;
      anxiety.&#xD;
&#xD;
      Neuronally, VS patients show cerebral hypermetabolism, resulting in altered neuronal&#xD;
      excitability, as well as increased grey matter volume in parts of the visual cortex.&#xD;
&#xD;
      For this pilot study, the investigators aim to recruit VS patients. In a double-blind,&#xD;
      randomized and placebo-controlled longitudinal experiment, the investigators will use&#xD;
      real-time functional magnetic resonance imaging (rtfMRI) neurofeedback to teach patients to&#xD;
      downregulate activity in different regions of the visual cortex.&#xD;
&#xD;
      The investigators hypothesize that neurofeedback will allow patients to learn to downregulate&#xD;
      their abnormal visual cortex activity. Moreover, the investigators predict that a stronger&#xD;
      downregulation of activity from the lingual gyrus will correlate with a more pronounced&#xD;
      decrease in VS symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, there is no pharmacological or non-pharmacological treatment available that&#xD;
      significantly reduces the high disease burden produced by VS. Thus, there is an unmet need&#xD;
      for an appropriate intervention to treat patients with VS. In this study, the investigators&#xD;
      will:&#xD;
&#xD;
        1. Test if rtfMRI-based neurofeedback could serve as therapeutic option for patients with&#xD;
           VS.&#xD;
&#xD;
           Here, the investigators will examine correlations of neurofeedback regulation success&#xD;
           with clinical scores 3 after neurofeedback&#xD;
&#xD;
        2. Examine brain function and structure in patients with VS&#xD;
&#xD;
      Primary and secondary endpoint/outcome(s)&#xD;
&#xD;
        -  Primary outcome variable: VS symptom severity before and after rtfMRI, using&#xD;
           standardized clinical assessment.&#xD;
&#xD;
        -  Secondary outcome variables: fMRI and structural MRI, clinical questionnaires (visual&#xD;
           function, anxiety, depression, tinnitus, and migraine), parameters from psychophysical&#xD;
           data (assessed before and after neurofeedback).&#xD;
&#xD;
        -  Linear Mixed model analysis will be performed (using clinical and imaging data) to&#xD;
           estimate the impact of rtfMRI on clinical progression and brain function/structure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In a double-blind, randomized and placebo-controlled longitudinal experiment, the investigators will use real-time functional magnetic resonance imaging (rtfMRI) neurofeedback to teach patients to downregulate activity in different regions of the visual cortex.&#xD;
50 patients (25 in each arm)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>symptom severity</measure>
    <time_frame>Acute after neurofeedback and 3 months after neurofeedback</time_frame>
    <description>Changes in symptom severity before and after real-time fMRI neurofeedback</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnetic resonance imaging</measure>
    <time_frame>before and immediately after the neurofeedback sessions</time_frame>
    <description>Assessment of Magnetic resonance imaging parameters related to brain function and structure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Visual Snow Syndrome</condition>
  <condition>Neuro-Ophthalmology</condition>
  <arm_group>
    <arm_group_label>Patients group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will regulate a brain region by real-time functional magnetic resonance imaging that is centrally involved in the visual snow syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This group will regulate a brain region by real-time functional magnetic resonance imaging that is not centrally involved in the visual snow syndrome</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neurofeedback</intervention_name>
    <description>(based on real-time functional magnetic resonance signals)</description>
    <arm_group_label>Patients group 1</arm_group_label>
    <arm_group_label>Patients group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with VS (≥ 18 to ≤ 60 years), which can read and sign the informed consent&#xD;
             form.&#xD;
&#xD;
          -  Male and female&#xD;
&#xD;
          -  Healthy controls (≥ 18 to ≤ 60 years), which can read and sign the informed consent&#xD;
             form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  MR exclusion criteria (patients only): metallic items in the body (i.e. eye splinter,&#xD;
             MR incompatible implants), pacemaker, claustrophobia).&#xD;
&#xD;
          -  pregnant participants&#xD;
&#xD;
          -  participants suffering from a degenerative disorder of the Central Nervous System,&#xD;
             such as Stroke, Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease and&#xD;
             Huntington's Disease and with major psychiatric disorders such as schizophrenia,&#xD;
             depression, or anxiety disorder requiring pharmacological treatment (psycho-pharmaca).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Lars Michels, Dr.</last_name>
      <phone>+41442554965</phone>
      <email>lars.michels@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Jeanette Popovova, Msc.</last_name>
      <email>Jeanette.popovova@usz.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>https://usz-foundation.com/projekte/weitere-projekte/</url>
    <description>Lists projects of the Iten-Kohaut foundation (our project is funded by this foundation)</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 20, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>August 1, 2021</last_update_submitted>
  <last_update_submitted_qc>August 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neurofeedback</keyword>
  <keyword>real-time functional magnetic resonance imaging</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The datasets presented in this study are not readily available because due to Swiss law, the researchers must assess whether the use of the data and coded datasets are within the primary scope of the informed consent. Subject level data is only available upon request and after the researchers have reviewed the purpose of the inquiry. Requests to access the datasets should be directed to Dr. Lars Michels, lars.michels@usz.ch.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

